Device Trial Radar · NCT03320096
Evaluation of the Ulthera System for Treating Axillary Hyperhidrosis
Last checked: Nov 20, 2026Latest source record: Jul 10, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Dec 13, 2016
Primary completion
Jun 19, 2017
Study completion Aug 22, 2017
Sponsor
- Lead sponsor
- Ulthera, IncNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 25, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the Ulthera System and the 7-3.0mm transducer for treating axillary hyperhidrosis.
Conditions
- Axillary Hyperhidrosis
Interventions
Microfocused ultrasound with visualizationDevice
Subjects will receive 2 treatments (day 1 and day 30), each at a 3.0mm depth and 0.30 Joule of energy. Treatment will be delivered in a 3\*4 grid, 12 treatment squares, delivering 60 lines of treatment per square, i.e., 720 lines per axilla in each treatment (1440 lines total per treatment.)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Hyperhidrosis Disease Severity Scale (HDSS) Score Reduction at Day 30 Post Second TreatmentTime frame: Day 60 (30 days post second treatment)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Rosenpark Research, Study Research Center; Merz Investigational Site #0490099
Darmstadt, Germany
Haut- & Laserzentrum, Merz Investigational Site #0490362
Potsdam, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.